207 related articles for article (PubMed ID: 26908305)
21. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
[TBL] [Abstract][Full Text] [Related]
22. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
Löwenstein O; Leyendecker P; Lux EA; Blagden M; Simpson KH; Hopp M; Bosse B; Reimer K
BMC Clin Pharmacol; 2010 Sep; 10():12. PubMed ID: 20920236
[TBL] [Abstract][Full Text] [Related]
24. Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.
Poulsen JL; Brock C; Grønlund D; Liao D; Gregersen H; Krogh K; Drewes AM
Dig Dis Sci; 2017 Nov; 62(11):3156-3166. PubMed ID: 28986667
[TBL] [Abstract][Full Text] [Related]
25. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
26. Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain.
Kim ES
Clin Drug Investig; 2017 Dec; 37(12):1191-1201. PubMed ID: 29098567
[TBL] [Abstract][Full Text] [Related]
27. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
28. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G; Fanelli A
Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
[TBL] [Abstract][Full Text] [Related]
29. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
Mercadante S; Giarratano A
Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.
Cuomo A; Russo G; Esposito G; Forte CA; Connola M; Marcassa C
Am J Hosp Palliat Care; 2014 Dec; 31(8):867-76. PubMed ID: 24249829
[TBL] [Abstract][Full Text] [Related]
31. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial.
Oppermann J; Bredow J; Spies CK; Lemken J; Unglaub F; Boese CK; Dargel J; Eysel P; Zöllner J
J Clin Anesth; 2016 Sep; 33():491-7. PubMed ID: 27555214
[TBL] [Abstract][Full Text] [Related]
32. Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial.
Schneider MP; Löffel LM; Furrer MA; Burkhard FC; Kleeb B; Curatolo M; Wuethrich PY
Pain; 2018 Mar; 159(3):560-567. PubMed ID: 29189517
[TBL] [Abstract][Full Text] [Related]
33. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
[TBL] [Abstract][Full Text] [Related]
34. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.
Tovoli F; De Lorenzo S; Samolsky Dekel BG; Piscaglia F; Benevento F; Brandi G; Bolondi L
Liver Int; 2018 Feb; 38(2):278-284. PubMed ID: 28792650
[TBL] [Abstract][Full Text] [Related]
35. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
36. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
Clemens KE; Mikus G
Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
[TBL] [Abstract][Full Text] [Related]
37. High doses of oxycodone-naloxone combination may provide poor analgesia.
Mercadante S; Ferrera P; Adile C
Support Care Cancer; 2011 Sep; 19(9):1471-2. PubMed ID: 21656338
[TBL] [Abstract][Full Text] [Related]
38. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation.
Rentz AM; Yu R; Müller-Lissner S; Leyendecker P
J Med Econ; 2009; 12(4):371-83. PubMed ID: 19912069
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
